@article{article_1716124, title={Prostat kanserinde Lutetium-177-PSMA tedavisi: tek merkezli gerçek yaşam deneyimi}, journal={Turkish Journal of Clinics and Laboratory}, volume={16}, pages={459–464}, year={2025}, DOI={10.18663/tjcl.1716124}, author={Akdoğan, Orhun and Sütçüoğlu, Osman and Gülbahar Ateş, Seda and Gürler, Fatih and Aydos, Uğuray and Savaş, Gözde and Akdemır, Ümit and Üner, Aytuğ and Atay, Lütfiye Özlem and Coşkun, Uğur and et al.}, keywords={Lutetium-177-PSMA, m-KRPK, radyoligand tedavi, PSA50, biyobelirteçler}, abstract={Aim: Lutetium-177–labeled PSMA radioligand therapy has emerged as a promising option in metastatic castration-resistant prostate cancer (mCRPC), yet real-world data remain limited. This study aimed to evaluate clinical features, treatment patterns, and predictors of response in patients treated with Lutetium-177-PSMA therapy at a single academic center. Material and Methods: We retrospectively analyzed 49 patients with mCRPC who received Lutetium-177-PSMA between January 2020 and January 2025. Treatment response was defined as a ≥50% decline in PSA (PSA50). Associations between baseline variables and PSA50 were examined using Mann–Whitney U tests, and predictive biomarkers were evaluated by receiver operating characteristic (ROC) analysis. Results: The PSA50 response rate was 41.7%. Lower baseline PSA (p = 0.023), ALP (p = 0.037), and LDH (p = 0.004) levels, and higher hemoglobin (p = 0.024), were significantly associated with response. Hemoglobin demonstrated the highest discriminatory performance (AUC = 0.692), while PSA, ALP, and LDH showed significant but limited predictive value. Treatment was well tolerated, with only one case of grade 3-4 hematologic toxicity. Conclusion: Lutetium-177-PSMA therapy provides clinical benefit in real-world mCRPC patients. Lower tumor burden and preserved hematologic status may predict better biochemical response, with hemoglobin serving as a moderately accurate biomarker. Prospective validation is warranted.}, number={3}, publisher={DNT Ortadoğu Yayıncılık A.Ş.}